Mistry described Scp776 as a “designer drug.” She explained that IGF-1 receptors are abundant throughout the body, and IGF-1 ...

For more than 40 years as a researcher and clinician, Joseph Broderick has actively contributed to improvements in stroke ...

Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from its Phase 2b clinical trial (LT3001-202) evaluating LT3001 (intravenous Odatroltide) in patients with acute ischemic stroke ...

Functional recovery after EVT for AIS varies by race and ethnicity, even though procedural success is similar across groups.

Predictors of short-term outcomes after endovascular therapy for acute ischemic stroke include age, neurologic status, and postsurgical complications, new research shows.

Patients who undergo general anesthesia while receiving a specialized surgery to treat strokes have better outcomes than ...

Argentina: A recent systematic review and meta-analysis published in the Journal of Thrombosis and Thrombolysis compared ...

A recent randomized clinical trial published in JAMA Neurology found that patients with large vessel occlusion acute ischemic stroke who underwent endovascular thrombectomy under general ...

Early diagnosis of stroke through wearables, advanced disease intervention and patient support through telemedicine, together contribute to novel stroke care.

An Advanced Stroke Care Centre is a specialized medical facility designed to deliver comprehensive, time-sensitive, and ...

Pat has a strong track record as a seasoned and strategic leader of medical technology companies, helping them catalyze new markets and scale internationally,” said Tony Chou, Chief Executive Officer ...

Key Highlights Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up to 24 hours after ...